GlassScriptPhysician profile
Dana C Dicharry
NPI 1588981864
$2,669.00
in general payments reported to CMS, 2019-2025
33 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $146 · 2021: $89.97 · 2022: $224 · 2023: $166 · 2024: $423 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.84 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $328.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $254.31 | 2019 | |
| Novo Nordisk INC | $225.61 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $169.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $144.42 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $109.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $95.80 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $88.88 | 2019-2020 | |
| Dexcom, INC. | $83.31 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $81.54 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $71.29 | 2019-2020 | |
| Amarin Pharma, INC. | $68.18 | 2019-2022 | |
| Abbott Laboratories | $62.74 | 2023-2024 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $50.29 | 2024-2025 | |
| Sanofi Pasteur INC. | $40.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.14 | 2019 | |
| Axsome Therapeutics, INC. | $23.58 | 2023 | Sunosi |
| Ardelyx, INC. | $18.57 | 2025 | Ibsrela |
| Vertex Pharmaceuticals Incorporated | $18.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.42 | 2024 | |
| Currax Pharmaceuticals LLC | $17.79 | 2024 | Onzetra Xsail, Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $17.75 | 2019 | |
| Exact Sciences Corporation | $17.57 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $17.05 | 2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $16.92 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.82 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.65 | 2025 | Voquezna |
| Gilead Sciences, INC. | $11.75 | 2022 | |
| Shire North American Group INC | $11.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Dicharry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.